Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Basel
- Most recent report
- 6-K, filed Oct 27, 2026
- Incorporated
- N/A
- Filings on record
- 1,002+ filings
- On EDGAR
- CIK 1114448
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 576
- 6-K Report a foreign issuer made public elsewhere Oct 27, 2026
- 6-K Report a foreign issuer made public elsewhere Sep 8, 2026
- 6-K Report a foreign issuer made public elsewhere Sep 4, 2026
- 6-K Report a foreign issuer made public elsewhere Sep 1, 2026
- 6-K Report a foreign issuer made public elsewhere Jul 21, 2026
- 6-K Report a foreign issuer made public elsewhere Jun 11, 2026
- 6-K Report a foreign issuer made public elsewhere Apr 28, 2026
- 6-K Report a foreign issuer made public elsewhere Mar 18, 2026
Prospectuses and Registrations 8 of 50
- FWP Free writing prospectus Nov 9, 2026
- 424B5 Prospectus supplement for an offering Nov 9, 2026
- 424B5 Prospectus supplement for an offering Mar 17, 2026
- FWP Free writing prospectus Mar 17, 2026
- 424B5 Prospectus supplement for an offering Mar 16, 2026
- S-8 Registration statement for an employee plan Feb 4, 2026
- S-8 POS Post-effective amendment to an employee plan registration Jan 16, 2026
- S-8 POS Post-effective amendment to an employee plan registration Jan 16, 2026
Ownership 8 of 170
- 144 Notice of a proposed sale of restricted stock Oct 28, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Oct 27, 2026
- 144 Notice of a proposed sale of restricted stock Apr 30, 2026
- 144 Notice of a proposed sale of restricted stock Feb 12, 2026
- 144 Notice of a proposed sale of restricted stock Feb 9, 2026
- 3 Insider reported their initial holding Oct 28, 2025
- SCHEDULE 13G Large holder reported a passive stake Jul 17, 2025
- 144 Notice of a proposed sale of restricted stock May 23, 2025
Other 8 of 206
Everything here comes from Novartis AG's own filings on SEC EDGAR. The filing list is rechecked every hour.